January 30, 2019
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)
Read More
January 30, 2019
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)
Read More
January 30, 2019
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Read More
January 30, 2019
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Read More
January 30, 2019
Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age
Read More
January 30, 2019
Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age
Read More
January 30, 2019
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
Read More
January 30, 2019
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
Read More
January 30, 2019
Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio’s DTPa-HBV-IPV/Hib Vaccine
Read More
January 30, 2019
Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio’s DTPa-HBV-IPV/Hib Vaccine
Read More
January 30, 2019
Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib Vaccine (GSK217744)
Read More
January 30, 2019
Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib Vaccine (GSK217744)
Read More
Load More
X